Last reviewed · How we verify

Docetaxel (XRP6976) — Competitive Intelligence Brief

Docetaxel (XRP6976) (Docetaxel (XRP6976)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; microtubule stabilizer. Area: Oncology.

phase 3 Taxane; microtubule stabilizer β-tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Docetaxel (XRP6976) (Docetaxel (XRP6976)) — Sanofi. Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in rapidly dividing cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Docetaxel (XRP6976) TARGET Docetaxel (XRP6976) Sanofi phase 3 Taxane; microtubule stabilizer β-tubulin
Docetaxel (D) Docetaxel (D) BeyondSpring Pharmaceuticals Inc. marketed Taxane; microtubule stabilizer β-tubulin
''albendazole'' and ''ivermectin'' ''albendazole'' and ''ivermectin'' Centre d'Appui à la lutte contre la Maladie marketed Antihelmintic/Antiparasitic agents β-tubulin (albendazole); glutamate-gated chloride channels (ivermectin)
Cabazitaxel (XRP6258) Cabazitaxel (XRP6258) Sanofi marketed Taxane; microtubule stabilizer β-tubulin (microtubule)
Docetaxel (DOC) Docetaxel (DOC) Sun Yat-sen University marketed Taxane; microtubule stabilizer β-tubulin
VIN VIN Italian Sarcoma Group marketed Vinca alkaloid; microtubule inhibitor β-tubulin
Paclitaxel (Pac) Paclitaxel (Pac) Aravive, Inc. marketed Taxane; microtubule stabilizer β-tubulin / microtubules

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; microtubule stabilizer class)

  1. Sanofi · 2 drugs in this class
  2. Aravive, Inc. · 1 drug in this class
  3. Athenex, Inc. · 1 drug in this class
  4. Barts & The London NHS Trust · 1 drug in this class
  5. BeyondSpring Pharmaceuticals Inc. · 1 drug in this class
  6. Bio-Thera Solutions · 1 drug in this class
  7. Dai, Guanghai · 1 drug in this class
  8. Fujian Medical University · 1 drug in this class
  9. Guangzhou Double Bioproducts Co., Ltd · 1 drug in this class
  10. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Docetaxel (XRP6976) — Competitive Intelligence Brief. https://druglandscape.com/ci/docetaxel-xrp6976. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: